Event in Progress:
Discover the latest content that has just been published on Research Tree
We are reiterating our Buy rating, projections and $22.50 price target for Betterware de Mexico with the company announcing 1Q24 (March) results after the close on Thursday. We believe, with momentum returning at the Betterware division, JAFRA remaining on a new product and marketing focus, the United States market becoming a larger emphasis and BWMX continuing to offer a compelling (and secure) dividend yield of 8.5%, BWMX remains well positioned to reward investors on multiple levels, and we r
Companies: NUS MED NUS BWMX MED DDMX
Small Cap Consumer Research LLC
We are reiterating our Buy rating, $22.50 price target and projections after reviewing Betterware de Mexico's April catalog. While the level of newness declined, perhaps due to the shifting Easter Holiday, the key positive trends remain, from higher YoY SKU levels, continued emphasis on full price selling, expansion into innovative adjacent categories and leveraging an improving supply chain to offer values in a still somewhat inflationary environment. As such, we remain upbeat on the potential
We are reiterating our Buy rating, $22.50 price target and projections for Betterware de Mexico after reviewing the March catalog. March completed a 1Q with material YoY positives, from higher SKU counts, rising cadence of new and debuting products, a return of key favorites and continued reductions in overall discounting levels. We believe Betterware management has been able to capitalize on the return to normalcy for their supply chain to roll out compelling new items, offer normalized pricing
We are raising our price target for BWMX to $22.50 (from $17) increasing our 2024 top and bottom line projections and rolling out 2025 projections after Betterware de Mexico registered 4Q upside on virtually every level, with the Betterware division returning to YoY top line growth for the first time in eight quarters, and 9.6% YoY revenue growth for JAFRA Mexico with materially better than expected margins. The company continued to reduce overall debt levels and raised the dividend rate by 25%,
We are reiterating our Buy rating, $17 price target and projections for Betterware de Mexico after reviewing the February catalog. We believe February was a continuation of multiple positive trends which increasingly convince us the division is on a solid path to return to positive top line growth: 1) strong YoY expansion of SKUs; 2) further reductions in overall discounting; and 3) continued new product excitement, from pet's to kids and Spring cleaning, Betterware continues to offer innovative
Companies: NUS NUS BWMX MED DDMX
Research Tree provides access to ongoing research coverage, media content and regulatory news on Medifast, Inc.. We currently have 0 research reports from 2 professional analysts.
Share: